Achieve Life Sciences, Inc. stockholders at the July 2, 2026, Annual Meeting approved a Certificate of Amendment to the Certificate of Incorporation to increase the number of authorized common stock shares from 150,000,000 to 300,000,000. The meeting also resulted in the election of nine directors to the board of directors and the following: PricewaterhouseCoopers LLP as the company's independent registered public accounting firm for the fiscal year 2026. Achieve Life Sciences, Inc. is a life sciences company that develops and commercializes commercial-stage drugs for the treatment of addiction-related disorders.